CHF Solutions’ Physician-Led Webinar Highlights Real-World Evidence Supporting Effectiveness of Ultrafiltration in Heart Fa...
January 28 2021 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced key takeaways from its physician-led webinar discussing
real-world experience using ultrafiltration (UF) in the management
of heart failure patients. Panelists discussed results from the
real-world retrospective study of 335 consecutive patients treated
with the Aquadex FlexFlow® System, published in Journal of Cardiac
Failure Supplement, that demonstrated UF compares favorably in
reducing heart failure rehospitalizations, renal function response,
and weight/volume loss.
Important clinical observations from the study include:
- Quantifying the amount of fluid
overload in a patient and whether they are adequately decongested
can be difficult. It is important to understand the patient as a
whole (i.e., medical history and weight at euvolemia stage).
- UF with Aquadex™ therapy adequately
decongests patients without significant injury to the kidneys, as
evidenced by reduced readmission rates, fluid loss, and serum
creatinine levels reported in the study.
- When treating patients with advanced
heart failure, it is important to know the cardiac output and
cardiac index, and if the cardiac index is low, the panelists
recommended support with inotropic therapy.
- When patients are not significantly
intravascularly volume overloaded, but have evidence of congestion
such as edema, using Aquadex at a low blood flow rate is an
effective solution to permit plasma refill.
- Aquadex allowed for a resetting of
the neurohormonal system and patients often were discharged on 50%
or less of their previous diuretic regimen.
- Early application of ultrafiltration
with Aquadex could improve patients’ outcomes sooner and quality of
life (i.e., reduce hospital length of stay).
“Ultrafiltration continues to be an effective solution for heart
failure patients as demonstrated by the decade of experience
included in the study conducted by the phenomenal team at
Abington-Jefferson,” said Nestor Jaramillo, Jr., President and
CEO of CHF Solutions. “We appreciate the panelists sharing
their extensive experience and thank them for their continued
dedication to expanding industry knowledge on the benefits of
effective fluid management.”
The webinar panelists included:
- Robert A. Watson III, MD, FAAC,
Chief, Cardiology Division, Co-Director, Comprehensive Heart
Failure Program at Abington Jefferson Health, Pennsylvania
- Donald C. Haas, MD, Medical
Director, Ventricular Assist Device Program; Co-Director,
Comprehensive Heart Failure Program at Abington Jefferson Health,
Pennsylvania
- Maureen Hummel, CRNP, Clinical
Director, Comprehensive Heart Failure Program at Abington Jefferson
Health, Pennsylvania
- Patti Barrella, MSN, CHFN, Heart
Failure Coordinator at Abington Jefferson Health, Pennsylvania
- John L. Jefferies, Jay M. Sullivan
Distinguished Chair in Cardiovascular Medicine and Chief of
Cardiology at the University of Tennessee Health Science
Center
You can access the webinar replay on the CHF Solutions’ website
and YouTube channel.
About CHF Solutions CHF
Solutions, Inc. (Nasdaq: CHFS) is a medical device company
dedicated to improving the lives of patients suffering from fluid
overload with its novel ultrafiltration therapy system. The company
is focused on developing, manufacturing and commercializing the
Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions
is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex System The Aquadex SmartFlow™
system delivers clinically proven therapy using a simple, flexible
and smart method of removing excess fluid from patients suffering
from hypervolemia (fluid overload). The Aquadex SmartFlow system is
indicated for temporary (up to 8 hours) or extended (longer than 8
hours in patients who require hospitalization) use in adult and
pediatric patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a health care provider, within
an outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the use of
Aquadex technology to treat heart failure patients. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
Matt Bacso, CFA
Gilmartin Group LLC
Matt.bacso@gilmartinir.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024